Craig Glazer, MD
Pulmonary Disease · Dallas, TXNPI 1497714521
Payments from drug & device makers
Across 5 payments — averaging $779.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$2K
- Boehringer Ingelheim International GmbH$2K
Across 132 payments — averaging $3524.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$452K
- Boehringer Ingelheim Pharma GmbH & Co.kg$9K
- Boehringer Ingelheim International GmbH$2K
- Boehringer Ingelheim Limited$2K
What the payments were for
- Speaking & faculty fees$1,89949%
- Grants$2,00051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $2,000 |
| Boehringer Ingelheim International GmbH | 4 | $1,899 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$1,899
How this compares
$3,899 in reported general payments places this provider in the 60th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 39 | $540,463 |
| Pirfenidone | 48 | $82,720 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $23,339 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $21,738 |
| Spiriva RespimatTiotropium Bromide | 14 | $12,758 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $11,422 |
| Arnuity ElliptaFluticasone Furoate | 20 | $5,620 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $5,205 |
| Mycophenolate Mofetil | 37 | $4,689 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $3,874 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $939 |
| Ipratropium Bromide | 15 | $408 |
| Montelukast Sodium | 15 | $164 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $154 |
| Prednisone | 39 | $70 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Dallas
- Yolanda MagetoDallas$239K
- Mark MillardDallas$192K
- Raksha JainDallas$153K
- Sonja BartolomeDallas$75K
- Kelly ChinDallas$72K
- Fernando TorresDallas$61K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.